Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-06-27 Purchase | 2024-07-01 08:00 am | Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner | 1,333,333 | $2.25 | $2,999,999 | 24,851,111 (Indirect Direct) | View |
| 2023-11-17 Purchase | 2023-11-20 07:35 am | Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner | 100,000 | $1.63 | $163,000 | 23,517,778 (Indirect) | View |
| 2023-08-24 Sale | 2023-08-25 4:30 pm | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 33,000 | $2.33 | $76,890 | 258,042 (Direct) | View |
| 2023-08-16 Purchase | 2023-08-16 8:57 pm | Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner | 16,466,667 | $0.9 | $14,820,000 | 23,417,778 (Indirect) | View |
| 2023-08-16 Purchase | 2023-08-16 8:53 pm | Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director | 777,778 | $0.9 | $700,000 | 1,933,671 (Indirect Direct) | View |
| 2023-08-16 Purchase | 2023-08-16 8:52 pm | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer | 444,444 | $0.9 | $400,000 | 1,536,715 (Indirect Direct) | View |
| 2023-08-16 Purchase | 2023-08-16 8:51 pm | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 111,111 | $0.9 | $100,000 | 114,111 (Direct) | View |
| 2023-07-12 Sale | 2023-07-14 4:00 pm | Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner | 85,872 | $0.70769 | $60,771 | 9,153,927 (Indirect Direct) | View |
| 2023-06-22 Sale | 2023-06-26 4:46 pm | Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner | 28,608 | $0.70327 | $20,119 | 9,239,799 (Indirect Direct) | View |
| 2023-06-20 Sale | 2023-06-22 4:00 pm | Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner | 434,615 | $0.70831 | $307,844 | 9,268,407 (Indirect Direct) | View |
| 2023-05-16 Purchase | 2023-05-18 4:44 pm | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D | 5,000 | $0.68 | $3,400 | 34,226 (Direct) | View |
| 2022-10-31 Purchase | 2022-11-02 4:09 pm | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 1,500,000 | $2 | $3,000,000 | 6,951,111 (Indirect Direct) | View |
| 2022-08-23 Sale | 2022-08-24 4:47 pm | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 3,325 | $3.47 | $11,538 | 266,121 (Direct) | View |
| 2022-08-18 Sale | 2022-08-22 8:05 pm | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 28,675 | $3.6966 | $105,999 | 269,446 (Direct) | View |
| 2022-07-05 Sale | 2022-07-07 4:30 pm | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D | 12,861 | $3.705 | $47,650 | 530,589 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-05-29 Option Award | 2024-05-31 4:18 pm | N/A 2034-05-29 | Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director | 147,660 | $0 | 2,081,331 (Direct) | View |
| 2024-05-29 Option Award | 2024-05-31 4:18 pm | N/A 2034-05-29 | Taysha Gene Therapies Inc. | TSHA | Long Alison S Director | 147,660 | $0 | 147,660 (Direct) | View |
| 2024-05-29 Option Award | 2024-05-31 4:18 pm | N/A 2034-05-29 | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 147,660 | $0 | 261,771 (Direct) | View |
| 2024-05-29 Option Award | 2024-05-31 4:15 pm | N/A 2034-05-29 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 147,660 | $0 | 147,660 (Direct) | View |
| 2024-02-02 Tax Withholding | 2024-02-06 4:42 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CHIEF FINANCIAL OFFICER | 1,288 | $1.51 | 840,937 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:43 pm | N/A 2034-01-02 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 590,413 | $0 | 1,432,638 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:42 pm | N/A 2034-01-02 | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D | 863,617 | $0 | 1,761,460 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:41 pm | N/A 2034-01-02 | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer | 1,184,688 | $0 | 3,906,091 (Direct) | View |
| 2023-12-14 Option Award | 2023-12-18 4:50 pm | N/A 2033-12-14 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 187,582 | $0 | 187,582 (Direct) | View |
| 2023-12-14 Option Award | 2023-12-18 4:47 pm | N/A 2033-12-14 | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D | 334,005 | $0 | 334,005 (Direct) | View |
| 2023-12-14 Option Award | 2023-12-18 4:46 pm | N/A 2033-12-14 | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer | 466,550 | $0 | 466,550 (Direct) | View |
| 2023-11-01 Option Award | 2023-11-03 4:41 pm | N/A 2033-11-01 | Taysha Gene Therapies Inc. | TSHA | Long Alison S Director | 43,800 | $0 | 43,800 (Direct) | View |
| 2023-08-16 Gift | 2023-08-16 8:53 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director | 50,000 | $0 | 1,933,671 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-26 4:50 pm | N/A 2033-06-22 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 36,200 | $0 | 36,200 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-26 4:50 pm | N/A 2033-06-22 | Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director | 36,200 | $0 | 36,200 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-26 4:49 pm | N/A 2033-06-22 | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 36,200 | $0 | 36,200 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-26 4:48 pm | N/A 2033-06-22 | Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director | 43,800 | $0 | 43,800 (Direct) | View |
Ownership | 2023-06-26 4:46 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director | 0 | $0 | 1,105,893 (Direct) | View |
| 2023-05-31 Option Award | 2023-06-02 4:12 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 6,230 | $0 | 291,042 (Direct) | View |
| 2023-03-06 Disposition | 2023-03-08 7:38 pm | N/A 2032-11-10 | Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner | 199,500 | $0 | 9,954,318 (Direct) | View |
| 2023-03-06 Other | 2023-03-08 7:38 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner | 251,296 | $0 | 9,954,318 (Direct) | View |
| 2023-02-02 Option Award | 2023-02-06 9:12 pm | N/A 2033-02-02 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer | 205,975 | $0 | 472,096 (Direct) | View |
| 2022-12-30 Option Award | 2023-01-04 4:51 pm | N/A 2032-12-30 | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer | 1,106,131 | $0 | 1,106,131 (Direct) | View |
| 2022-12-30 Option Award | 2023-01-04 4:51 pm | N/A 2032-12-30 | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D | 790,093 | $0 | 790,093 (Direct) | View |
| 2022-11-10 Option Award | 2022-12-23 4:15 pm | N/A 2032-11-10 | Taysha Gene Therapies Inc. | TSHA | Session R.A. II Director 10% Owner | 199,500 | $0 | 199,500 (Direct) | View |
Ownership | 2022-10-31 4:05 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Audentes Therapeutics Inc. Astellas Pharma Inc. 10% Owner | 0 | $0 | 7,266,342 (Direct) | View |